Actualités

Stock Market Today: The Dow Jones index slashed its gains after Trump's new threats on Iran. Oracle stock plunged on earnings.

Everyone wants to get in on the action. That generally doesn't make the best investing opportunities.

(Bloomberg) -- Retail traders’ infatuation with high-flying computer memory and storage companies is fading now that the next big thing — SpaceX’s initial public offering — is on the way. Most Read from BloombergXbox Plans Significant Layoffs as New CEO Plans OverhaulHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’US Strikes Iran in Trump Escalation Over Stalled Peace TalksTech Stocks Sink as Oil Jumps on US-Iran Jitters: Markets WrapOracle Falls After Data Center Costs Overshadow A

Oracle beat Wall Street expectations on revenue and profit, but investors balked at a new $40 billion financing plan for its AI buildout

The move comes after Oracle reported larger-than-expected capital expenditures to fund its data center buildout—with more significant spending on the way. The company reported $55.7 billion in capital expenditures for its latest fiscal year, higher than the $50 billion Oracle previously forecast.

Hopes for lower interest rates are fading fast, putting renewed pressure on bond prices — and fixed-income investors' portfolios.

Investing.com -- Intel shares climbed about 5% in premarket trading after Bank of America double-upgraded the stock from Underperform to Buy and raised its price target to $135 from $96, driven by growing confidence in the company’s server CPU opportunity and its external foundry business.

Most investors fear lingering inflation will chip away at Dollar General's foot traffic, which has defied the odds so far.

Oracle (NYSE:ORCL) reported quarterly earnings and revenue ahead of market forecasts on Wednesday and raised its outlook for annual adjusted earnings per share. Despite the strong operating performance, the stock fell 10.

SpaceX (SPCX) started trading on Friday following the biggest IPO ever.

SpaceX (SPCX) started trading on Friday following the biggest IPO ever.

Buying SpaceX stock after June 12 is only one way to get exposure following the biggest IPO in history. Here are the three ways in, and what to know about each investment method.

A short-term correction will not prevent long-term catalysts from taking shape.

New Fed Chair Kevin Warsh and the Federal Open Market Committee (FOMC) may be forced to tackle rapidly rising inflation.

The legendary investor preached the value of buying good companies at reasonable prices.

The market looked set to rebound on Thursday as investors piled back into tech stocks, which have taken a beating in recent days due to worries about higher inflation and the looming SpaceX IPO. “We remain constructive on the long-term bull market, but mounting technical evidence suggests an increased risk of a deeper pullback,” said LPL Financial’s chief technical strategist Adam Turnquist. The European Central Bank is widely expected to hike interest rates for the first time in nearly three years, which could foreshadow future tightening by the Federal Reserve and other central banks.

Oracle beat Q4 earnings and sealed a $300B OpenAI deal. Flat guidance sent shares down 8%. The AI bet has a price.

SpaceX offers dominance, but Rocket Lab offers greater upside.

The Nasdaq Composite tumbled again today after the latest inflation reading and higher oil prices failed to stop the bleeding. Chips were at the heart of the downturn, with the iShares Semiconductor ETF sinking another 3.7%, putting the chip stock benchmark 12% off its June 3 closing high. Industrials were the biggest laggard on Wednesday, dragged down by a swirl of other factors including rising oil prices, and expectations of a Fed interest rate hike.

Could you be better off steering clear of the SpaceX IPO, or is this one reason good enough to buy?

US stock futures tumbled amid reports that the US struck Iran hours after President Trump had pledged to do so, saying negotiations were taking "too long."

Anterix (ATEX) delivered earnings and revenue surprises of +26.79% and +23.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

You can't spell SpaceX without "space," but the company could be shifting its focus to another hot tech trend.

Investors may be having second thoughts about Caterpillar’s part in the AI data-center construction boom as a supplier of power generators. For Caterpillar, it’s the biggest drop in more than a year, when shares declined 5.78% on April 4, 2025. Shares are down four of the last five trading sessions and off since the start of June, according to Dow Jones Market Data.

Quantinuum's public debut didn't attract much attention.

Navan stock surges after the AI-focused corporate travel company surpassed Wall Street’s expectations with first-quarter earnings and raised guidance.

Oracle (ORCL) reported fourth quarter results on Wednesday after the closing bell. Adjusted earnings per share (EPS) came in at $2.11 (compared to analyst estimates of $1.97), and adjusted revenue came in at $19.18 billion (compared to analyst estimates of $19.09 billion). Yahoo Finance's Josh Lipton takes a closer look at the breaking numbers.

Global stock markets mostly fell on Wednesday as fresh strikes in the Middle East, a jump in US inflation and a tech sell-off weighed on sentiment.While the headline figure jumped, the core reading that excludes energy prices that have surged due to war in the Middle East, held steady at 2.9 percent.

Investing.com -- Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while maintaining its $25 price target. The brokerage said the stock's roughly 11% pullback from its 2026 highs has brought valuation in line with its expectations, reducing the downside risks it had previously highlighted.

Investing.com -- Illumina received a bullish rating upgrade from JPMorgan, which raised its recommendation to Overweight from Neutral and lifted its December 2026 price target to $185 from $125, citing growing confidence in the DNA sequencing company's ability to sustain strong growth despite increasing competition.